SCHEMBL6922267

SCHEMBL6922267

O=c1c2ccc(-c3cccc(F)c3)cc2nc2n1CCN(Cc1ccccc1)C2

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM2 Q14416 1/20 0.48
ALDH1A1 P00352 5/20 0.47
SMN1; SMN2 Q16637 4/20 0.47
PKM P14618 1/20 0.47
USP2 O75604 6/20 0.47
HSD17B10 Q99714 5/20 0.47
KDM4E B2RXH2 4/20 0.47
HPGD P15428 2/20 0.47
LMNA P02545 2/20 0.47
GAA P10253 2/20 0.47
ADORA2A P29274 1/20 0.45
ADORA1 P30542 1/20 0.45
CLPP Q16740 1/20 0.44
BCL2A1 Q16548 2/20 0.44
BID P55957 1/20 0.44
GABRA1 P14867 1/20 0.44
GABRA2 P47869 1/20 0.44
DRD2 P14416 2/20 0.42
DRD4 P21917 2/20 0.42
DRD3 P35462 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12059614 0.91 ALDH1A1 (0.53) ALDH1A1SMN1; SMN2PKMUSP2HSD17B10
SCHEMBL6921007 0.85 GRM2 (0.46) GRM2ALDH1A1SMN1; SMN2PKMUSP2
SCHEMBL6921795 0.85 GRM2 (0.46) GRM2SMN1; SMN2BCL2A1
SCHEMBL6923595 0.84 GRM2 (0.41) GRM2ALDH1A1BCL2A1BID
SCHEMBL6920958 0.83 GRM2 (0.45) GRM2ADORA2AADORA1BCL2A1
SCHEMBL6922513 0.82 RXFP1 (0.45) GRM2ALDH1A1SMN1; SMN2USP2HSD17B10
SCHEMBL6922377 0.81 LMNA (0.41) GRM2SMN1; SMN2LMNABCL2A1CYP2C19
SCHEMBL6921025 0.81 ALDH1A1 (0.52) GRM2ALDH1A1SMN1; SMN2PKMUSP2
SCHEMBL6923042 0.81 RAB9A (0.39) GRM2SMN1; SMN2HPGDLMNABCL2A1
SCHEMBL6923330 0.77 KDM4E (0.58) ALDH1A1SMN1; SMN2USP2HSD17B10KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2011075699-A2 COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF SUNOVION PHARMACEUTICALS INC. (US) 2011-06-23 WO disclosed